Sandra D. van der Vaart, EVP and Chief Legal Officer at Laboratory Corporation of America Holdings (LH), has demonstrated a consistent selling bias in her recent insider transactions, with no open-market purchases recorded in the past two years. Since 2024, her Form 4 filings reveal $5.32 million in total sales against $512,971 in acquisitions, all involving LH stock. The most significant disposals occurred on August 13, 2025 ($1.06 million) and March 26, 2026 ($730,530), with additional sales of $155,999 each on February 27, 2026. Smaller but repeated transactions appear throughout 2025 and early 2026, including multiple sales under $30,000 executed alongside option exercises (coded "M") that show no accompanying purchase value.
Van der Vaart’s activity suggests a pattern of systematic divestment rather than discretionary trading, with sales occurring across multiple quarters. The transactions include both open-market disposals (code "S") and dispositions following option exercises (code "F"), with the latter accounting for smaller amounts like $25,482 on February 9, 2026, and $27,997 on February 6, 2026. While her role as Chief Legal Officer implies routine equity compensation, the absence of any recent buys—combined with the scale and frequency of sales—indicates a net reduction in her LH holdings over time. The filings show no material acquisitions since the $512,971 transaction on August 13, 2025, which was offset by a same-day sale of more than double that amount.
AI-assisted summary